• Agreement with Mayo Clinic to enable distribution of EchoSolv HF post FDA clearance
• EchoSolv AS deployed with leading US health system Mount Sinai
• Robust US pipeline with over 50 active accounts, 3 closed-won contracts

Echo IQ Limited (ASX: EIQ) has provided an update on its activities during the three-month period ended 31 March 2026. Key highlights include an agreement with Mayo Clinic to enable distribution of EchoSolv HF post FDA clearance, deployment of EchoSolv AS with leading US health system Mount Sinai, and a robust US pipeline with over 50 active accounts and 3 closed-won contracts. The company has also expanded its US sales and implementation team to provide full regional coverage and enhance its ability to convert pipeline opportunities and ensure successful onboarding and long-term retention. EchoSolv AS usage has accelerated, with a 131% quarter-on-quarter growth in echocardiograms processed, highlighting increasing integration into clinical workflows and the platform's ability to operate at scale within leading institutions. Echo IQ has also strengthened its commercial readiness through expansion of its intellectual property and brand portfolio, filing 10 new patents and 4 new trademarks across key global jurisdictions.

The potential progression of EchoSolv HF through the FDA represents a significant near-term catalyst, as entry into the heart failure market materially expands Echo IQ's addressable opportunity and provides a natural upsell pathway across its existing customer base.

Echo IQ is focused on converting its pipeline into revenue, progressing key regulatory milestones, and continuing to scale the platform to deliver long-term, sustainable growth for shareholders.